The maintenance of a Buy rating and an $8 price target by a reputable analyst like Stephen Willey from Stifel suggests a strong belief in Cue Biopharma's potential for growth. This endorsement is likely to instill confidence in investors and could lead to a positive short-term impact on the stock's price.